Clinical Trial Update: SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SCH 66336 (lonafarnib) in combination with gemcitabine for advanced cancers of the urinary tract has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Carcinoma of the Urethra
• Transitional Cell Carcinoma of the Renal Pelvis and Ureter

Drugs mentioned

• Gemcitabine (Gemcitabine)
• SCH 66336 (lonafarnib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Status: COMPLETED